pembrolizumabRecent, repeatedEvidence- NCT07890714 · Daiichi Sankyo · Phase 2 · live · background · “Pembrolizumab” · registered Oct 2026
- NCT07865910 · Fosun Pharma · Phase 3 · live · comparator · “PEMBROLIZUMAB (alone or when added to a regimen above)” · registered Oct 2026
- NCT07845786 · Exelixis · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2026
- NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pembrolizumab” · registered Aug 2026
- NCT07756645 · AbbVie · Phase 3 · live · comparator · “Pembrolizumab” · registered Aug 2026
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 5686 studies | 5384 studies | background 73 · comparator 55 · standard-care 1 |
CarboplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “cisplatin or carboplatin” · registered Oct 2026
- NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Carboplatin injection” · registered Oct 2026
- NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Carboplatin” · registered Oct 2026
- NCT07865910 · Fosun Pharma · Phase 3 · live · background · “Carboplatin (Investigator discretion)” · registered Oct 2026
- NCT07845786 · Exelixis · Phase 2 · live · background · “Carboplatin” · registered Sep 2026
| Eli Lilly and Company16% of its industry studies | 53109 studies | 49116 studies | background 214 · comparator 61 · standard-care 1 |
PemetrexedRecent, repeatedEvidence- NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “pemetrexed” · registered Oct 2026
- NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Pemetrexed Disodium For Injection” · registered Oct 2026
- NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Pemetrexed” · registered Oct 2026
- NCT07865910 · Fosun Pharma · Phase 3 · live · background · “Pemetrexed (1)” · registered Oct 2026
- NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
| Eli Lilly and Company67% of its industry studiesUS: off-patent, 4 generics marketedEU: off-patent, 3 generics authorized | 4791 studies | 4599 studies | background 131 · comparator 66 · standard-care 1 |
DocetaxelRecent, repeatedEvidence- NCT07821684 · AbbVie · Phase 3 · live · comparator · “Docetaxel” · registered Sep 2026
- NCT07668752 · Genfleet Therapeutics (Shanghai) Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
- NCT07660094 · Candel Therapeutics, Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Jun 2026
- NCT07609251 · Sinocelltech Group Limited · Phase 2 · live · background · “docetaxel” · registered May 2026
- NCT07566052 · Astellas Pharma Inc · Phase 3 · live · comparator · “Docetaxel” · registered Apr 2026
| Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized | 3438 studies | 3849 studies | comparator 65 · background 59 |
CisplatinRecent, repeatedEvidence- NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “cisplatin or carboplatin” · registered Oct 2026
- NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Cisplatin injection” · registered Oct 2026
- NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Cisplatin” · registered Oct 2026
- NCT07822542 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · background · “Cisplatin” · registered Sep 2026
- NCT07777822 · Revolution Medicines, Inc. · Phase 3 · live · background · “pemetrexed + cisplatin /carboplatin” · registered Aug 2026
| Eli Lilly and Company28% of its industry studiesUS: off-patent, 6 generics marketed | 3065 studies | 3176 studies | background 111 · comparator 48 · standard-care 1 |
PaclitaxelRecent, repeatedEvidence- NCT07871214 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Oct 2026
- NCT07845786 · Exelixis · Phase 2 · live · background · “Paclitaxel” · registered Sep 2026
- NCT07756645 · AbbVie · Phase 3 · live · background · “Paclitaxel” · registered Aug 2026
- NCT07739199 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2026
- NCT07680764 · Bristol-Myers Squibb · Phase 2 · live · background · “Paclitaxel” · registered Jun 2026
| Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed | 2342 studies | 2244 studies | background 134 · comparator 33 |
osimertinibRecent, repeatedEvidence- NCT07897188 · Beijing Aosaikang Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “osimertinib” · registered Oct 2026
- NCT07680790 · Bristol-Myers Squibb · Phase 3 · live · background · “Osimertinib” · registered Jun 2026
- NCT07669779 · Akeso · Phase 2 · live · background · “Osimertinib” · registered Jun 2026
- NCT07642024 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Osimertinib” · registered Jun 2026
- NCT07640789 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Osimertinib” · registered Jun 2026
| AstraZeneca93% of its industry studiesUS: AstraZeneca (FDA 2015)EU: AstraZeneca (EMA 2016) | 1627 studies | 2132 studies | background 31 · comparator 6 |
tislelizumabRecent, repeatedEvidence- NCT07896005 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Tislelizumab Injection” · registered Oct 2026
- NCT07846358 · Genfleet Therapeutics (Shanghai) Inc. · Phase 2 · live · background · “with or without Tislelizumab” · registered Sep 2026
- NCT07822542 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Tislelizumab” · registered Sep 2026
- NCT07739186 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Tislelizumab” · registered Jul 2026
- NCT07672223 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Tislelizumab” · registered Jun 2026
| BeOne Medicines72% of its industry studiesUS: BeOne Medicines (FDA 2024)EU: BeOne Medicines (EMA 2023) | 1516 studies | 1416 studies | comparator 11 · background 6 |
Albumin-Bound PaclitaxelRecent, repeatedEvidence- NCT07845786 · Exelixis · Phase 2 · live · background · “Nab-paclitaxel” · registered Sep 2026
- NCT07756645 · AbbVie · Phase 3 · live · background · “Nab- Paclitaxel” · registered Aug 2026
- NCT07662395 · Sinocelltech Group Limited · Phase 3 · live · background · “Nab-paclitaxel” · registered Jun 2026
- NCT07365319 · Eikon Therapeutics · Phase 3 · live · background · “Nab-paclitaxel + Carboplatin” · registered Jan 2026
- NCT07221474 · Merck & Co., Inc · Phase 2 · live · background · “Nab-paclitaxel” · registered Oct 2025
| Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008) | 1117 studies | 1219 studies | background 34 · comparator 3 |
NivolumabRecent, repeatedEvidence- NCT07672223 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Nivolumab” · registered Jun 2026
- NCT07541170 · Hoffmann-La Roche · Phase 3 · live · comparator · “Nivolumab” · registered Apr 2026
- NCT07246863 · CatalYm GmbH · Phase 2 · live · background · “Nivolumab” · registered Nov 2025
- NCT07195695 · Boehringer Ingelheim · Phase 3 · live · comparator · “Nivolumab” · registered Sep 2025
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 99 studies | 1212 studies | background 23 · comparator 4 |
GemcitabineRecent, repeatedEvidence- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Gemcitabine” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Gemcitabine + Nab-paclitaxel” · registered May 2025
- NCT07005336 · TJ Biopharma Co., Ltd. · Phase 2 · live · background · “Gemcitabine” · registered May 2025
- NCT06908304 · Maia Biotechnology · Phase 3 · live · comparator · “Gemcitabine alone” · registered Mar 2025
- NCT06623422 · Merck & Co., Inc · Phase 3 · live · background · “Gemcitabine” · registered Sep 2024
| Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed | 67 studies | 1018 studies | background 41 · comparator 20 |
BevacizumabRecent, repeatedEvidence- NCT06730750 · Bristol-Myers Squibb · Phase 2 · live · background · “Bevacizumab” · registered Dec 2024
- NCT06512051 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Bevacizumab Injection” · registered Jul 2024
- NCT06303505 · Gilead Sciences · Phase 2 · live · background · “Bevacizumab” · registered Feb 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Aug 2023
- NCT05579366 · Genmab · Phase 2 · live · background · “Bevacizumab” · registered Oct 2022
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 67 studies | 66 studies | background 15 · comparator 17 |
durvalumabRecent, repeatedEvidence- NCT07672223 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Durvalumab” · registered Jun 2026
- NCT07554339 · Merck & Co., Inc · Phase 3 · live · background · “Durvalumab” · registered Apr 2026
- NCT07361497 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Durvalumab” · registered Jan 2026
- NCT07195695 · Boehringer Ingelheim · Phase 3 · live · comparator · “Durvalumab” · registered Sep 2025
- NCT06667908 · Johnson & Johnson · Phase 2 · live · background · “Durvalumab” · registered Oct 2024
| AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018) | 67 studies | 67 studies | comparator 10 · background 5 |
CetuximabRecent, repeatedEvidence- NCT07939815 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Nov 2026
- NCT07468071 · Novartis · Phase 2 · live · background · “cetuximab” · registered Mar 2026
- NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “cetuximab (Cohort C2 Only)” · registered Feb 2026
- NCT07223047 · Bristol-Myers Squibb · Phase 2 · live · background · “Cetuximab” · registered Oct 2025
- NCT07020221 · Verastem, Inc. · Phase 2 · live · background · “Cetuximab” · registered May 2025
| Eli Lilly and Company33% of its industry studiesUS: Eli Lilly and Company (FDA 2004)EU: Merck KGaA, Darmstadt, Germany (EMA 2004) | 69 studies | 56 studies | background 14 · comparator 1 |
CrizotinibRecent, repeatedEvidence- NCT07816380 · Guangzhou JOYO Pharma Co., Ltd · Phase 3 · live · comparator · “Crizotinib Capsules” · registered Sep 2026
- NCT06564324 · Nuvation Bio Inc. · Phase 3 · live · comparator · “Crizotinib” · registered Aug 2024
- NCT06140836 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Crizotinib” · registered Nov 2023
- NCT06082635 · Shenzhen TargetRx, Inc. · Phase 3 · live · comparator · “Crizotinib” · registered Oct 2023
- NCT05204628 · Sihuan Pharmaceutical Holdings Group Ltd. · Phase 3 · live · comparator · “Crizotinib” · registered Dec 2021
| Pfizer94% of its industry studiesUS: Pfizer (FDA 2011)EU: Pfizer (EMA 2012) | 55 studies | 88 studies | comparator 11 · background 2 |
cemiplimabRecent, repeatedEvidence- NCT06090266 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2023
- NCT05317858 · insightec · Phase 3 · live · background · “Cemiplimab” · registered Mar 2022
- NCT05259696 · Palleon Pharmaceuticals, Inc. · Phase 2 · background · “Cemiplimab” · registered Feb 2022
- NCT05208944 · Maia Biotechnology · Phase 2 · live · background · “Cemiplimab” · registered Dec 2021
- NCT05094804 · OncoResponse, Inc. · Phase 2 · live · background · “Cemiplimab” · registered Sep 2021
| Regeneron Pharmaceuticals83% of its industry studiesUS: Regeneron Pharmaceuticals (FDA 2018)EU: Regeneron Pharmaceuticals (EMA 2019) | 44 studies | 34 studies | background 6 |
Antineoplastic AgentsRecent, repeatedEvidence- NCT07874984 · 3SBio Inc. · Phase 2 · live · background · “Chemotherapy” · registered Sep 2026
- NCT06228326 · Krystal Biotech, Inc. · Phase 2 · live · background · “Chemotherapy” · registered Jan 2024
- NCT05787613 · Fosun Pharma · Phase 2 · live · background · “Chemotherapy drug” · registered Mar 2023
- NCT05098990 · China Resources Pharmaceutical Group Limited · Phase 4 · comparator · “Platinum-based doublet chemotherapy” · registered Sep 2021
- NCT04951648 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · comparator · “chemotherapy” · registered Jun 2021
| — | 33 studies | 44 studies | background 9 · comparator 7 |
VinorelbineRecent, repeatedPhase 4 trial recordedEvidence- NCT06908304 · Maia Biotechnology · Phase 3 · live · comparator · “Vinorelbine” · registered Mar 2025
- NCT06564844 · AstraZeneca · Phase 3 · live · comparator · “Vinorelbine” · registered Aug 2024
- NCT05487391 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Vinorelbine Tartrate” · registered Aug 2022
- NCT03770299 · Bristol-Myers Squibb · Phase 2 · background · “Vinorelbine” · registered Dec 2018
- NCT03456076 · Hoffmann-La Roche · Phase 3 · live · comparator · “Vinorelbine” · registered Mar 2018
| Eli Lilly and Company9% of its industry studies | 33 studies | 44 studies | comparator 10 · background 3 |
ivonescimabRecent, repeatedEvidence- NCT07603791 · Shanghai Allink Biotherapeutics Co., Ltd. · Phase 2 · live · background · “Ivonescimab Injection” · registered May 2026
- NCT07397338 · Revolution Medicines, Inc. · Phase 2 · live · background · “Ivonescimab” · registered Feb 2026
- NCT07208773 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 2 · live · background · “Ivonescimab” · registered Sep 2025
| Akeso81% of its industry studies | 33 studies | 33 studies | background 3 |
toripalimabRecent, repeatedEvidence- NCT06623136 · Elpiscience (Suzhou) Biopharma, Ltd. · Phase 2 · live · background · “Toripalimab” · registered Sep 2024
- NCT05955105 · Innolake Biopharm · Phase 2 · live · background · “Toripalimab” · registered Jul 2023
- NCT05386888 · Genfleet Therapeutics (Shanghai) Inc. · Phase 2 · background · “Toripalimab” · registered May 2022
| RemeGen Co., Ltd.15% of its industry studiesUS: Coherus Biosciences, Inc. (FDA 2023)EU: Topalliance Biosciences Europe Limited (EMA 2024) | 33 studies | 22 studies | background 3 |
DexamethasoneRecent, repeatedEvidence- NCT06305754 · Merck & Co., Inc · Phase 3 · live · background · “Dexamethasone (or equivalent)” · registered Mar 2024
- NCT05663866 · Johnson & Johnson · Phase 2 · live · background · “Dexamethasone” · registered Dec 2022
- NCT05070247 · Takeda · Phase 2 · background · “Dexamethasone” · registered Sep 2021
- NCT04786964 · Sun Pharmaceutical Industries Limited · Phase 3 · background · “Dexamethasone 4mg” · registered Mar 2021
- NCT04300556 · Eisai Co., Ltd. · Phase 2 · live · background · “Dexamethasone” · registered Mar 2020
| AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016) | 22 studies | 33 studies | background 13 |
IpilimumabRecent, repeatedEvidence- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
- NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Ipilimumab” · registered Aug 2023
- NCT04665206 · Vivace Therapeutics, Inc · Phase 2 · live · background · “Nivolumab & Ipilimumab” · registered Dec 2020
- NCT03989362 · Jounce Therapeutics, Inc. · Phase 2 · background · “Ipilimumab” · registered Jun 2019
- NCT03739710 · GlaxoSmithKline · Phase 2 · background · “Ipilimumab” · registered Nov 2018
| Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011) | 22 studies | 33 studies | background 11 |
atezolizumabRecent, repeatedEvidence- NCT07195695 · Boehringer Ingelheim · Phase 3 · live · comparator · “Atezolizumab” · registered Sep 2025
- NCT05317858 · insightec · Phase 3 · live · background · “Atezolizumab” · registered Mar 2022
- NCT04984811 · NeoImmuneTech · Phase 2 · background · “Atezolizumab” · registered Jul 2021
- NCT04471415 · Dracen Pharmaceuticals, Inc. · Phase 2 · background · “atezolizumab” · registered Jun 2020
- NCT04440735 · Kahr Medical · Phase 2 · live · background · “Atezolizumab” · registered Jun 2020
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 22 studies | 33 studies | comparator 1 · background 8 |
CapecitabineRecent, repeatedEvidence- NCT06253871 · Iambic Therapeutics, Inc · Phase 2 · live · background · “Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab” · registered Feb 2024
- NCT05785741 · DualityBio Inc. · Phase 2 · live · background · “capecitabine” · registered Mar 2023
- NCT05091528 · Silverback Therapeutics · Phase 2 · background · “capecitabine” · registered Oct 2021
- NCT03169738 · ImmunityBio, Inc. · Phase 2 · background · “Capecitabine” · registered May 2017
- NCT00732810 · Merck & Co., Inc · Phase 2 · comparator · “Capecitabine” · registered Aug 2008
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 22 studies | 22 studies | background 4 · comparator 1 |
EtoposideRecent, repeatedEvidence- NCT06564844 · AstraZeneca · Phase 3 · live · comparator · “Etoposide” · registered Aug 2024
- NCT05298423 · Merck & Co., Inc · Phase 3 · background · “etoposide” · registered Mar 2022
- NCT04380636 · Merck & Co., Inc · Phase 3 · live · background · “Etoposide” · registered May 2020
- NCT04203511 · Incyte Corporation · Phase 3 · background · “Etoposide” · registered Dec 2019
- NCT03840902 · Merck KGaA, Darmstadt, Germany · Phase 2 · background · “Etoposide” · registered Feb 2019
| Hoffmann-La Roche14% of its industry studiesUS: off-patent, 5 generics marketed | 22 studies | 22 studies | comparator 2 · background 4 |
enzalutamideRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Enzalutamide” · registered Sep 2022
- NCT04557449 · Pfizer · Phase 2 · live · background · “Enzalutamide” · registered Sep 2020
- NCT03568656 · CellCentric Ltd. · Phase 2 · background · “Enzalutamide” · registered Jun 2018
| Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized | 22 studies | 22 studies | background 3 · comparator 1 |
trametinibRecent, repeatedEvidence- NCT07468071 · Novartis · Phase 2 · live · background · “trametinib” · registered Mar 2026
- NCT05358249 · Novartis · Phase 2 · background · “trametinib” · registered Apr 2022
- NCT05275374 · Xynomic Pharmaceuticals, Inc. · Phase 2 · live · background · “Trametinib” · registered Feb 2022
- NCT02580708 · Clovis Oncology, Inc. · Phase 2 · background · “Trametinib” · registered Oct 2015
- NCT01336634 · Novartis · Phase 2 · background · “Trametinib” · registered Apr 2011
| GlaxoSmithKline49% of its industry studiesEU: Novartis (EMA 2014) | 23 studies | 22 studies | background 5 |
RamucirumabRecent, repeatedEvidence- NCT07821684 · AbbVie · Phase 3 · live · comparator · “Ramucirumab” · registered Sep 2026
- NCT07098338 · AstraZeneca · Phase 2 · live · background · “Ramucirumab” · registered Jul 2025
- NCT06448754 · AstraZeneca · Phase 2 · live · background · “Ramucirumab” · registered Jun 2024
- NCT04394624 · Sanofi · Phase 2 · background · “ramucirumab” · registered May 2020
| Eli Lilly and Company91% of its industry studiesUS: Eli Lilly and Company (FDA 2014)EU: Eli Lilly and Company (EMA 2014) | 23 studies | 23 studies | background 3 · comparator 1 |
sotorasibRecent, repeatedEvidence- NCT07563738 · Orion Corporation, Orion Pharma · Phase 2 · live · background · “sotorasib” · registered Apr 2026
- NCT06497556 · Hoffmann-La Roche · Phase 3 · live · comparator · “Sotorasib” · registered Jul 2024
| Amgen86% of its industry studiesUS: Amgen (FDA 2021)EU: Amgen (EMA 2022) | 22 studies | 22 studies | background 1 · comparator 1 |
aflutinibRecent, repeatedEvidence- NCT07622186 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 2 · live · background · “Furmonertinib” · registered May 2026
- NCT06962865 · RemeGen Co., Ltd. · Phase 2 · live · background · “Furmonertinib Mesilate Tablets Monotherapy” · registered Apr 2025
| Allist Pharmaceuticals, Inc.52% of its industry studies | 22 studies | 22 studies | background 2 |
CyclophosphamideRecent, repeatedEvidence- NCT05566223 · Intima Bioscience, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Sep 2022
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Cyclophosphamide” · registered Jun 2022
- NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “cyclophosphamide” · registered Apr 2019
- NCT03574649 · ImmunityBio, Inc. · Phase 2 · background · “Cyclophosphamide” · registered Jun 2018
- NCT03169738 · ImmunityBio, Inc. · Phase 2 · background · “cyclophosphamide” · registered May 2017
| Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed | 22 studies | 11 study | background 12 |
Abiraterone AcetateRecent, repeatedEvidence- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
- NCT05551117 · MacroGenics · Phase 2 · comparator · “Abiraterone” · registered Sep 2022
- NCT03568656 · CellCentric Ltd. · Phase 2 · background · “Abiraterone acetate” · registered Jun 2018
- NCT02711137 · Incyte Corporation · Phase 2 · background · “Abiraterone” · registered Mar 2016
| Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 11 study | background 3 · comparator 1 |
aldesleukinRecent, repeatedEvidence- NCT05566223 · Intima Bioscience, Inc. · Phase 2 · background · “Aldesleukin” · registered Sep 2022
- NCT05267626 · Aulos Bioscience, Inc. · Phase 2 · live · background · “Aldesleukin” · registered Feb 2022
| Chiron Corporation45% of its industry studiesUS: Chiron Corporation (FDA 1992) | 22 studies | 11 study | background 2 |
fludarabineRecent, repeatedPhase 4 trial recordedEvidence- NCT05566223 · Intima Bioscience, Inc. · Phase 2 · background · “Fludarabine” · registered Sep 2022
- NCT05451849 · TCR2 Therapeutics · Phase 2 · background · “Fludarabine” · registered Jun 2022
- NCT03907852 · TCR2 Therapeutics · Phase 2 · live · background · “fludarabine” · registered Apr 2019
| Beijing Biotech18% of its industry studies | 22 studies | 11 study | background 3 |